welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
The Muscular Dystrophy Association161 N. Clark, Suite 3550
Chicago, Illinois, United States
Email Phone Web
The Muscular Dystrophy Association is committed to transforming the lives of individuals affected by neuromuscular disease. MDA accomplishes their mission through innovations in science and innovations in care. As the largest source of funding for neuromuscular disease research in the US outside of the federal government, MDA has invested more than $1 billion to accelerate the discovery of treatments. MDA also supports a nationwide network of care centers at more than 150 top institutions where individuals with muscular dystrophy, ALS and more than 40 other neuromuscular diseases can access expert clinical care. In addition, MDA also operates a National Resource Center and provides educational and social events, summer camp and programing across the country, at no cost to families.
Here are some of MDA’s current highlights:
- Today, dozens of clinical trials are in progress thanks in part to MDA’s long-term research investments
- MDA is currently funding more than 170 grants in 11 countries, with a total commitment of more than $46 million.
- MDA awarded 81 new research grants in 2017 with a total funding commitment of more than $18 million
- MDA’s National Resource Center: 1-833-ASK-MDA1 (1-833-275-6321)
Duchenne Muscular Dystrophy Research TermsAdeno-Associated Viral (AAV) Adeno-asso...
Raising awareness for Duchenne Muscular DystrophyConnor has Duchenne Muscular Dystrophy a...
Parent Project Muscular DystrophyParent Project Muscular Dystrophy (PPMD)...
Ohio woman creates free coloring books featuring kids with disabilities in memory of her sonWhen Sue Nuenke remembers her son Chris ...
Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship ProgramSarepta Therapeutics, Inc. (NASDAQ:SRPT)...
Kerry JohnsonKerry Johnson is a Senior Operations and...
How Facebook and Twitter could be the next disruptive force in clinical trialsAmber Sapp was browsing the Internet lat...